natgillin/translations-raw huggingface dataset:
In the pivotal trials conducted by the MAH, a dose higher than the dose proposed was used and, as very limited final height data is available, the clinical relevance of the effect was not demonstrated. 
Ker je na voljo zelo malo podatkov o končni telesni višini, kliničen pomen učinka ni bil dokazan.
The Bechtold study, the only one where the proposed dose (0.047 mg/kg/day) was used, did not reveal any glucose abnormalities. 
V Bechtoldovi študiji, ki je edina, v kateri so uporabili predlagani odmerek (0,047 mg/kg/dan), niso odkrili nenormalnosti v zvezi z glukozo, vendar pri teh bolnikih sladkorna bolezen ostaja težava, saj dolgoročni učinki kombinacije rastnega hormona in kortikosteroidov niso znani in niso bili raziskani.
The study was conducted in 2 centers in France and included a total of 30 subjects who received Genotropin at the dose of 0.066 mg/kg/day. 
Zajela je skupno 30 bolnikov, ki so prejemali zdravilo Genotropin v odmerku 0,066 mg/kg/dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Enbrel on 3 February 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Enbrel, veljavno po vsej Evropski uniji, izdala 3. februarja 2000.
What measures are being taken to ensure the safe and effective use of Enbrel? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Enbrel?
In all of the studies, the main measure of effectiveness was the change in symptoms. 
V vseh študijah je bilo glavno merilo učinkovitosti sprememba simptomov.
The full EPAR for Enbrel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Enbrel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week. 
Običajni priporočeni odmerek pri odraslih je 25 mg dvakrat na teden ali 50 mg enkrat na teden.
Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis. 
Zdravljenje s 50 mg dvakrat na teden se lahko uporabi tudi v prvih 12 tednih zdravljenja psoriaze v plakih.
This is a summary of the European public assessment report (EPAR) for Enbrel. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Enbrel.
A risk management plan has been developed to ensure that Enbrel is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Enbrel je bil pripravljen načrt obvladovanja tveganj.
The CHMP decided that Enbrel's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Enbrel večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
For patients below 18 years of age, the dose depends on body weight. 
Pri bolnikih, mlajših od 18 let, je treba količino odmerka prilagoditi telesni masi.
By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases. 
Z zaviranjem TNF etanercept zmanjša vnetje in blaži druge simptome bolezni.
Enbrel was also compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, 1,263 adults and 211 children with plaque psoriasis, as well as in 225 patients with non-radiographic axial spondyloarthritis. 
Zdravilo Enbrel so primerjali tudi s placebom pri 51 otrocih s poliartikularnim juvenilnim idiopatskim artritisom, 205 odraslih s psoriatičnim artritisom, 357 odraslih z ankilozirajočim spondilitisom, 1 263 odraslih in 211 otrocih s psoriazo v plakih ter pri 225 bolnikih z neradiografskim aksialnim spondilitisom.
What benefit has Enbrel shown during the studies? 
Kakšne koristi je zdravilo Enbrel izkazalo med študijami?
Other information about Enbrel 
Druge informacije o zdravilu Enbrel
The most common side effects with Enbrel (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections). 
Najpogostejši neželeni učinki zdravila Enbrel (opaženi pri več kot 1 od 10 bolnikov) so reakcije na mestu injiciranja (vključno s krvavitvami, podplutbami, pordelostjo, srbenjem, bolečino in otekanjem) in okužbe (vključno s prehladi ter okužbami pljuč, mehurja in kože).
Etanercept is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA) that makes them able to produce etanercept. 
Etanercept se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori etanercept.
Enbrel must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections. 
Zdravila Enbrel ne smejo uporabljati bolniki, ki imajo sepso ali pri katerih obstaja nevarnost sepse (ko bakterije in toksini krožijo v krvi in začnejo povzročati poškodbe organov) ali bolniki z okužbami.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enbrel. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What is the risk associated with Enbrel? 
Kakšna tveganja so povezana z zdravilom Enbrel?
For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo after three to four months. 
Pri vseh drugih boleznih, ki so jih raziskovali, je zdravilo Enbrel po treh do štirih mesecih povzročilo večje izboljšanje simptomov kot placebo.
The studies in children with polyarticular juvenile idiopathic arthritis and plaque psoriasis were followed up with long term studies to assess the safety of long term treatment in children. 
Študijam pri otrocih s poliartikularnim juvenilnim idiopatskim artritisom in psoriazo v plakih so sledile dolgotrajne študije, da bi ocenili varnost dolgotrajnega zdravljenja pri otrocih.
The company that makes Enbrel will provide educational material for doctors expected to prescribe the product (to teach patients how to use the pre-filled pen correctly) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor). 
Družba, ki proizvaja zdravilo Enbrel, bo zagotovila izobraževalno gradivo za zdravnike, ki naj bi predpisovali zdravilo (za učenje pravilne uporabe predhodno napolnjenega peresnika) in bolnike (da bi lahko prepoznali morebitne resne neželene učinke ter tako vedeli, kdaj naj nujno poiščejo pomoč pri zdravniku).
For more information about treatment with Enbrel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Enbrel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Enbrel can also be used in patients with severe rheumatoid arthritis who have not taken methotrexate before; 
Zdravilo Enbrel se lahko uporablja tudi pri bolnikih s hudim revmatoidnim artritisom, ki pred tem metotreksata niso jemali;
Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine. 
Bolniki, ki jemljejo zdravilo Enbrel, morajo prejeti posebno opozorilno kartico, ki povzema varnostne podatke o zdravilu.
• certain forms of juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in the following groups: 
• določenih oblik juvenilnega idiopatskega artritisa (redke otroške bolezni, ki povzroča vnetje več sklepov) pri naslednjih skupinah:
The patient or carer can give the injection if they have been trained appropriately. 
Zdravilo lahko injicira bolnik ali njegov negovalec, če sta za to ustrezno usposobljena.
In the study of patients who had not taken methotrexate before, those receiving 25 mg Enbrel twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months. 
V študiji, v kateri so sodelovali bolniki, ki pred tem metotreksata niso jemali, so po 12 in 24 mesecih pri bolnikih, ki so prejemali 25 mg zdravila Enbrel dvakrat na teden, ugotovili manj poškodb sklepov kot pri tistih, ki so jemali samo metotreksat.
Enbrel is given by injection under the skin. 
Zdravilo Enbrel se injicira pod kožo.
Enbrel has been studied in five main studies in rheumatoid arthritis, involving about 2,200 patients and lasting from three months to two years. 
Zdravilo Enbrel so pri revmatoidnem artritisu raziskovali v petih glavnih študijah, v katerih je sodelovalo približno 2 200 bolnikov, trajale pa so od treh mesecev do dveh let.
Why has Enbrel been approved? 
Zakaj je bilo zdravilo Enbrel odobreno?
• plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in patients from the age of six years with long-term severe disease;. 
• psoriaze v plakih (bolezni, ki povzroča rdeče, luskaste zaplate na koži) pri odraslih z zmernim do hudim obolenjem in bolnikih, starejših od šest let, z dolgotrajno hudo boleznijo.
Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat. 
Zdravljenje z zdravilom Enbrel lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se uporablja zdravilo Enbrel.
Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease. 
Zdravilo Enbrel se uporablja pri bolnikih, ki se niso odzvali na druga zdravila za te bolezni ali pa jih ne smejo prejemati.
The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF). 
Etanercept, zdravilna učinkovina v zdravilu Enbrel, je beljakovina, ki je bila zasnovana tako, da v telesu zavre aktivnost kemičnega prenašalca, imenovanega tumorje nekrotizirajoči faktor (TNF).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Enbrel, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection. 
Na voljo je v vialah, ki vsebujejo prašek za pripravo raztopine za injiciranje, ter v napolnjenih injekcijskih brizgah in peresnikih, ki vsebujejo raztopino za injiciranje.
The long term safety studies found that Enbrel could be used in polyarticular juvenile idiopathic arthritis in children from the age of two years and plaque psoriasis from the age of six years. 
Študije o dolgoročni varnosti zdravila so pokazale, da se zdravilo Enbrel lahko uporablja za zdravljenje juvenilnega idiopatskega artritisa pri otrocih, starejših od dveh let, in psoriaze v plakih pri otrocih, starejših od šest let.
• moderate to severe rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults (aged 18 years or over). 
• zmernega do hudega revmatoidnega artritisa (bolezni imunskega sistema, ki povzroča vnetje sklepov) pri odraslih (starih 18 let ali več).
One of these studies examined Enbrel's effects as an add-on to methotrexate in 89 patients. 
V eni izmed teh študij so pri 89 bolnikih raziskovali učinke zdravila Enbrel, ki so ga uporabili kot dodatek metotreksatu.
Overall, in the studies of rheumatoid arthritis, about two-thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months. 
V vseh študijah revmatoidnega artritisa se je pri približno dveh tretjinah bolnikov, ki so prejemali zdravilo Enbrel, po treh mesecih jakost simptomov zmanjšala za 20 % ali več.
Patients developing a serious infection should stop Enbrel treatment. 
Bolniki, pri katerih se pojavi resna okužba, morajo zdravilo Enbrel prenehati jemati.
The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients. 
V peti študiji pa so pri 686 bolnikih primerjali učinkovitost zdravila Enbrel in učinkovitost metotreksata ter kombinacijo obeh zdravil.
Enbrel is a medicine that contains the active substance etanercept. 
Enbrel je zdravilo, ki vsebuje zdravilno učinkovino etanercept.
Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient. 
Zdravilo Enbrel se uporablja skupaj z metotreksatom (zdravilom, ki učinkuje na imunski sistem) pri odraslih z zmernim do resnim obolenjem, ki so se neustrezno odzvali na druge načine zdravljenja, ali kot samostojno zdravilo, če metotreksat za bolnika ni primeren.
patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate; 
bolnikih, starih od dve do 17 let, ki imajo poliartritis (pozitiven ali negativen revmatoidni faktor) in razširjen oligoartritis ter se niso ustrezno odzvali na zdravljenje z metotreksatom ali pa ga ne prenašajo;
In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone. 
V peti študiji se je izkazalo, da je bilo zdravilo Enbrel, ki so ga dajali samostojno ali v kombinaciji z metotreksatom, bolj učinkovito kot metotreksat, ki so ga bolniki jemali samostojno.
Enbrel is an anti inflammatory medicine. 
Zdravilo Enbrel je protivnetno zdravilo.
For the full list of all side effects reported with Enbrel, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Enbrel, glejte navodilo za uporabo.
This messenger is found at high levels in patients with the diseases that Enbrel is used to treat. 
Ta prenašalec je prisoten v velikih koncentracijah pri bolnikih z boleznimi, za zdravljenje katerih se uporablja zdravilo Enbrel.
• severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments; 
• hudega ankilozirajočega spondilitisa (bolezni, ki povzroča vnetje in bolečine v sklepih hrbtenice) pri odraslih, ki se niso ustrezno odzvali na druge vrste zdravljenja;
• Severe non-radiographic axial spondyloarthritis (a chronic inflammatory disease of the spine) when there are objective signs of inflammation but no abnormalities seen on x-ray. 
• hudega neradiografskega aksilnega spondilitisa (kroničnega vnetnega obolenja hrbtenice), kadar so stvarni znaki vnetja prisotni, rentgenska slika pa ne kaže nepravilnosti.
In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before. 
V četrti študiji so pri 632 bolnikih, ki pred tem metotreksata niso jemali, zdravilo Enbrel primerjali z metotreksatom.
How has Enbrel been studied? 
Kako je bilo zdravilo Enbrel raziskano?
What is Enbrel used for? 
Za kaj se zdravilo Enbrel uporablja?
This compared with around a quarter of the patients receiving placebo. 
Pri bolnikih, ki so prejemali placebo, pa se je jakost simptomov zmanjšala le pri približno četrtini bolnikov.
How is Enbrel used? 
Kako se zdravilo Enbrel uporablja?
Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken arthritis medicines in the past. 
V treh študijah so pri bolnikih, ki so v preteklosti jemali zdravila za zdravljenje artritisa, zdravilo Enbrel primerjali s placebom (zdravilom brez zdravilne učinkovine).
adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate; adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment. 
mladostnikih, starih od 12 do 17 let, ki imajo psoriatični artritis (bolezen, ki povzroča rdeče, luskaste zaplate na koži in vnetje sklepov) in se niso ustrezno odzvali na zdravljenje z metotreksatom ali pa ga ne prenašajo;
What is Enbrel? 
Kaj je zdravilo Enbrel?
How does Enbrel work? 
Kako zdravilo Enbrel deluje?
Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the member states 
PRILOGA I SEZNAM IMEN, FARMACEVTSKA OBLIKA/E, JAKOST/I ZDRAVIL/A, POT/I UPORABE, PREDLAGATELJ/I, IMETNIK/I DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Chiesi Pharmaceuticals GmBH Gonzagagasse 16/6 Vienna A-1010 Austria 
Madžarska Chiesi Pharmaceuticals GmBH Gonzagagasse 16/16 Vienna A-1010
Food increases the bioavailability from 80 % to 90 %. 
Hrana poviša biodostopnost od 80% do 90 %.
ATCvet code: QC03DA01. 
Oznaka ATC_vet: QC03DA01.
Pharmacotherapeutic group: Aldosterone antagonist. 
Farmakoterapevtska skupina: Antagonist aldosterona.
(Mortality was classified as death or euthanasia due to heart failure). 
( smrtnost je bila klasificirana kot pogin ali eutanazija zaradi srčne odpovedi. )
Très le Bois 22600 Loudéac France 
Très le Bois 22600 Loudéac Francija
This is thought to be due to activation of feedback mechanisms without adverse clinical consequence. 
To je posledica aktivacije povratnih mehanizmov brez neželenih kliničnih posledic.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMA) http://www.ema.europa.eu
It is therefore recommended to induce vomiting, gastric lavage (depending on risk assessment) and monitor electrolytes. 
Priporočljivo je izzvati bruhanje, izprati želodec (odvisno od ocene tveganja) in monitoring elektrolitov.
Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction. 
Čeprav natančen mehanizem delovanja še ni definiran, aldosteron pospešuje miokardialno fibrozo, miokardialno in vaskularno preoblikovanje in endotelialno disfunkcijo.
After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels from 32 % to 49 % of the administered dose. 
Po peroralnem dajanju spironolaktona psom se je pokazalo, da trije metaboliti dosežejo nivoje od 32% do 49% danega odmerka.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could therefore affect the metabolism of other drugs utilizing these metabolic pathways. 
Spironolakton lahko povzroči indukcijo in inhibicijo citokrom P450 encimov in lahko vpliva na metabolizem drugih zdravil, ki uporabljajo te metabolne poti.
The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding. 
Tableta se lahko primeša manjšemu delu hrane, ki se ponudi živali pred obrokom ali pa se da tableto neposredno v usta živali po hranjenju.
Ceva Santé Animale ensures that the system of pharmacovigilance, as described in Part I of the marketing authorisation application, is in place and functioning before and whilst the veterinary medicinal product is on the market. 
Ceva Santé Animale zagotavlja, da je sistem farmakovigilance, kot je opisan v delu I vloge za pridobitev dovoljenja za promet, vzpostavljen in deluje, preden je zdravilo za uporabo v veterinarski medicini v prometu in ves čas trženja zdravila.
Artificial beef flavour Compressible sugar Magnesium stearate 
Umetna aroma govedine Stisljiv sladkor Magnezijev stearat
Catalent Germany Schorndorf GmbH Steinbeistrasse 2 
Catalent Germany Schorndorf GmbH Steinbeistrasse 2 D-73614 Schorndorf Nemčija
The tablets contain beef flavouring to improve palatability, and a study conducted in healthy dogs showed that they were voluntarily and fully consumed 75% of the time. 
Tablete vsebujejo govejo aromo za izboljšanje okusnosti in študija opravljena na zdravih psih je pokazala, da v 75% psi pojedo tableto prostovoljno in v celoti.
Cardboard box containing 3 or 18 blisters of 10 tablets. 
Kartonska škatla s 3 ali 18 pretisnimi omoti po 10 tablet.
Do not use after the expiry date which is stated on the carton after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP.
Plasma clearance of canrenone is 1.45±0.39 l/h/kg and 7α-thiomethyl-spironolactone is 0.89±0.44 l/h/kg. 
Plazemski klirens kanrenona je 1.45±0.39 l/h/kg in 7α-tiometil-spironolaktona 0.89±0.44 l/h/kg.
The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively. 
Volumna distribucije (Vss) 7α-tiometil-spironolaktona in kanrenona sta približno 153 in 177 litrov.
In case of an accidental massive ingestion by the dog, there is no specific antidote or treatment. 
V primeru, da pes nenamerno zaužije veliko količino zdravila, ne obstaja specifičen protistrup ali zdravilo.
Do not use during pregnancy and lactation, laboratory studies in species (rat, mouse, rabbit and monkey) have shown evidence of developmental toxicity. 
Ne uporabite v obdobju brejosti in laktacije, laboratorijske študije na podganah, miših, kuncih in opicah so pokazale primere razvojne toksičnosti.
Administer 2 mg/kg of body weight of spironolactone once daily. 
Odmerite 2 mg/kg telesne mase spironolaktona enkrat dnevno.
Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia. 
Ne uporabite pri psih, ki so oboleli za hipoadenokorticizmom, hiperkaliemijo ali hiponatriemijo.
Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration. 
Spironolakton zmanjša izločanje digoksina in zatorej poveča koncentracijo digoksina v plazmi.
In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure. 
Pri eksperimentalnih vzorcih pri psih se je pokazalo, da dolgotrajna terapija z antagonisti aldosterona prepreči progresivno disfunkcijo in zmanjša preoblikovanje levega prekata pri psih s kronično srčno odpovedjo.
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone. 
Pri kliničnih testiranjih psov s kronično srčno odpovedjo, so rezultati pokazali 65% zmanjšanje rizičnosti smrtnosti pri 15 mesečnih psih, ki so bili tretirani s spironolaktonom v kombinaciji s standardno terapijo kot pri psih,ki so bili zdravljeni samo s standardno terapijo.
Lactose monohydrate Cellulose, microcrystalline Crospovidone Povidone K30 
Laktoza monohidrat Celuloza, mikrokristalna Krospovidon Povidon K30
After oral administration of radiolabelled spironolactone to the dog, 70 % of the dose is recovered in faeces and 20 % in the urine. 
Po peroralnem dajanju radiološko označenega spironolaktona psom so ugotovili 70 % odmerka v blatu in 20 % v urinu.